12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Botox onabotulinumtoxinA regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Botox onabotulinumtoxinA from Allergan to prevent chronic migraines in patients who have not responded to at least 3 preventative medications and whose headaches are not being caused by medication overuse. The FAD says treatment with Botox should not continue if there is less than a 30% reduction in...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >